Comparison of short-term efficacy between 1-month and 3-month depot gonadotropin-releasing hormone agonist in girls with central precocious puberty.

Purpose Gonadotropin-releasing hormone agonist (GnRHa) has been the mainstay of central precocious puberty (CPP) treatment for decades, although there have been few reports comparing the efficacy between 1-month and 3-month depot GnRHa formulations. This study aimed to investigate the short-term efficacy of 1-month and 3-month depot GnRHa in girls with CPP. Methods Overall, 150 girls with CPP were included from a retrospective review of their medical records. Subjects in group 1 (n=105) were treated with 1-month depot GnRHa for ≥12 months and those in group 2 (n=45) with 1-month depot for 6 months and subsequent 3-month depot GnRHa for ≥6 months. Anthropometric and biochemical data were compared between groups at three time points (0, 6, and 12 months after GnRHa treatment). Results Demographic and clinical characteristics showed no difference between groups at baseline and 6 months after GnRHa treatment. After 12 months of GnRHa treatment, patients in both groups showed no difference in bone age (BA), chronological age (CA), BA-CA difference, height standard deviation score (SDS) for CA and BA, and body mass index SDS for CA and BA. The sexual maturity rate of the breast was prepubertal at 12 months in all subjects. GnRH-stimulated luteinizing hormone (LH) levels were suppressed during GnRHa treatment in both groups at 6 and 12 months, although LH levels in group 2 were higher than those in group 1. Conclusion Treatment with a 3-month depot GnRHa in CPP showed comparable short-term efficacy to the 1-month depot for anthropometric parameters and pubertal suppression.